Allopurinol
- Generic Name
- Allopurinol
- Brand Names
- Aloprim, Zyloprim
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4O
- CAS Number
- 315-30-0
- Unique Ingredient Identifier
- 63CZ7GJN5I
- Background
Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals .
...
- Indication
Allopurinol is indicated in :
1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
...
- Associated Conditions
- Hyperuricemia, Primary Gout, Recurrent calcium oxalate calculi, Secondary gout, Calcium oxalate calculi Renal Calculi
- Associated Therapies
- -
Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT01129648
Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)
- Conditions
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2011-01-06
- Lead Sponsor
- Nuon Therapeutics, Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT01109121
- Locations
- 🇺🇸
Nuon Investigative Site, Spokane, Washington, United States
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 6198
- Registration Number
- NCT01101035
Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 180
- Registration Number
- NCT01092221
- Locations
- 🇮🇱
Lev Hasharon Mental Health Center, Zur-Moshe, Israel
🇮🇱Sheba Medical Center, Ramat-Gan, Israel
🇷🇴Spitalul de Psihiatrie, si Neurologie, Brasov, Brasov, Romania
Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones
- Conditions
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 99
- Registration Number
- NCT01077284
Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia
- Conditions
- Interventions
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2011-01-06
- Lead Sponsor
- Nuon Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01052987
- Locations
- 🇺🇸
Nuon Investigative Site, Dallas, Texas, United States
Impact of Diabetes on Left Ventricular Remodeling
- Conditions
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 72
- Registration Number
- NCT01052272
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Allopurinol Combination Study
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT01001338
Allopurinol in Chronic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2009-10-19
- Lead Sponsor
- National Heart and Lung Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00997542
- Locations
- 🇬🇧
Royal Brompton Hospital, London, United Kingdom
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
- Conditions
- Interventions
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Duke University
- Target Recruit Count
- 253
- Registration Number
- NCT00987415
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Morehouse School of Medicine, Atlanta, Georgia, United States
🇺🇸University Hospitals-Case Medical Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.